BMJ Public Health retracted a controversial study that alleged a link between COVID-19 vaccines and excess mortality after an institutional investigation. The decision removes a frequently cited claim from the scientific record and highlights how quickly vaccine safety narratives can evolve when evidence is challenged. For biotech, the retraction underscores the importance of study-quality scrutiny and transparency in pharmacoepidemiology, especially as safety surveillance increasingly feeds into payer and regulatory discussions. The episode may also affect how stakeholders interpret downstream analyses that depend on underlying methodologies and dataset integrity.